Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01556386

Enrollment

200

Registered

2012-03-16

Start date

2006-06-30

Completion date

2012-05-31

Last updated

2014-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia

Keywords

acute lymphoblastic leukemia, single nucleotide polymorphism

Brief summary

This study is to find out distribution of genetic polymorphisms and genes related to the chemotherapeutic drugs of ALL.

Detailed description

Cure rate of pediatric ALL dramatically improved over 80%. Resistance to drug and hematologic relapse are remaining problem in ALL treatment. One of the explanations of drug resistance and toxicities is the pharmacogenetic effect. Germline polymorphisms in genes that code for proteins involved in the pharmacokinetics and pharmacodynamics of antileukemic agents are various, and inter-patient variability is the main factor for pharmacogenetic difference. Since multiple chemotherapeutic agents are involved in treating ALL, many genes related to the metabolic pathways of those drugs have an effect on the pharmacokinetics of patients with ALL. In Korea, pharmacogenetic study including multiple genetic loci for pediatric ALL has not been reported.In this study, the distribution of genetic polymorphisms and genes related to antileukemic drugs were analyzed, and their relations to the outcome of treatment and relapse rates were assessed.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 21 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of acute lymphoblastic leukemia * In case of informed consent and assent

Exclusion criteria

* Paients or parents refusal

Design outcomes

Primary

Measure	Time frame	Description
To find out distribution of genetic polymorphisms genes related to the pharmacodynamics of the ALL therapy	up to 3 years from diagnosis	* The distribution of each genetic polymorphism is descriped. * The differences in genetic polymorphism between risk groups (high vs. standard) are analyzed using the chi-square test or Fisher's exact test.

Secondary

Measure	Time frame	Description
To see the ethnic difference of genetic polymorphisms related to the chemotehrapeutic drugs of ALL	whenever after diagnosis and genetic analysis (no time frame needed)	• The differences in genetic polymorphism between other populations (Korean vs. Western or Japanese) are analyzed using the chi-square test or Fisher's exact test.
To find out relation of genetic polymorphisms and clinical outcome (relapse or survival)	up to 3 years from diagnosis	\- Event-free and overall survival are estimated using Kaplan-Meier analysis, and the survival differences according to different genetic polymorphisms and prognostic variables are analyzed by log-rank test.
To find out risk factors of relapse and death	up to 3 years from diagnosis	\- Multivariate analysis is conducted with Cox proportional hazards regression model to analyze predictive factors. For the multivariate analysis, all significant univariate variables are entered in a stepwise, forward-selection protocol.

Countries

South Korea

Outcome results